These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35508710)

  • 1. Higher incidence of neurotoxicity and skin hyperpigmentation in renal transplant patients treated with polymyxin B.
    Zhou Y; Li Y; Xie X; Song L; Lan G; Sun B; Tang T; Yan H; Zhang B; Xu P
    Br J Clin Pharmacol; 2022 Nov; 88(11):4742-4750. PubMed ID: 35508710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skin hyperpigmentation following intravenous polymyxin B treatment associated with melanocyte activation and inflammatory process.
    Mattos KPH; Cintra ML; Gouvêa IR; Ferreira LÁ; Velho PENF; Moriel P
    J Clin Pharm Ther; 2017 Oct; 42(5):573-578. PubMed ID: 28497462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymyxin B vs. colistin: the comparison of neurotoxic and nephrotoxic effects of the two polymyxins.
    Aysert-Yildiz P; Özgen-Top Ö; Şentürk AF; Kanik S; Özger HS; Dizbay M
    BMC Infect Dis; 2024 Aug; 24(1):862. PubMed ID: 39187812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective observational study of the treatment with polymyxin B for liver transplantation recipients infected by multidrug-resistant gram-negative bacteria.
    Yu LL; Shi XP; Huang JF; Gong Y; Cui CX; Wang T
    J Clin Pharm Ther; 2022 Oct; 47(10):1563-1569. PubMed ID: 35670240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurotoxicity in patients treated with intravenous polymyxin B: Two case reports.
    Weinstein L; Doan TL; Smith MA
    Am J Health Syst Pharm; 2009 Feb; 66(4):345-7. PubMed ID: 19202043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymyxin B-induced skin hyperpigmentation: a rare case report and literature review.
    Zheng G; Cao L; Che Z; Mao E; Chen E; He J
    BMC Pharmacol Toxicol; 2018 Jul; 19(1):41. PubMed ID: 29973293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperpigmentation on head and neck caused by polymyxin B: A rare case.
    Kaya F; Tuğcugil E
    Niger J Clin Pract; 2023 Sep; 26(9):1393-1395. PubMed ID: 37794556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe Infusion-Related Adverse Events and Renal Failure in Patients Receiving High-Dose Intravenous Polymyxin B.
    John JF; Falci DR; Rigatto MH; Oliveira RD; Kremer TG; Zavascki AP
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymyxin B-induced skin hyperpigmentation.
    Li YM; Milikowski C; Selvaggi G; Abbo LM; Skiada D; Galimberti F
    Transpl Infect Dis; 2020 Oct; 22(5):e13312. PubMed ID: 32386075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Risk factors for acute kidney injury in patients treated with polymyxin B experience from 139 cases at a tertiary university hospital in Colombia].
    Osorio J; Barreto J; Samboni CF; Cándelo LA; Álvarez LC; Benavidez S; Téllez RP; Santofimio D; Ramos JA; Gómez CA
    Rev Chilena Infectol; 2017 Feb; 34(1):7-13. PubMed ID: 28394975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nephrotoxicity in Patients with or without Cystic Fibrosis Treated with Polymyxin B Compared to Colistin.
    Crass RL; Rutter WC; Burgess DR; Martin CA; Burgess DS
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute toxicity is a dose-limiting factor for intravenous polymyxin B: A safety and pharmacokinetic study in healthy Chinese subjects.
    Liu X; Chen Y; Yang H; Li J; Yu J; Yu Z; Cao G; Wu X; Wang Y; Wu H; Fan Y; Wang J; Wu J; Jin Y; Guo B; Hu J; Bian X; Li X; Zhang J
    J Infect; 2021 Feb; 82(2):207-215. PubMed ID: 33453286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymyxin B clinical outcomes: A prospective study of patients undergoing intravenous treatment.
    Mattos KPH; Gouvêa IR; Quintanilha JCF; Cursino MA; Vasconcelos PENS; Moriel P
    J Clin Pharm Ther; 2019 Jun; 44(3):415-419. PubMed ID: 30666679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histopathological findings of pigmented lesion and recovery of natural skin colour in a patient with polymyxin B-associated diffuse hyperpigmentation.
    Zavascki AP; Schuster LF; Duquia RP
    Int J Antimicrob Agents; 2016 Nov; 48(5):579-580. PubMed ID: 27720305
    [No Abstract]   [Full Text] [Related]  

  • 15. [Analysis of risk factors of polymyxin B-associated acute kidney injury in intensive care unit patients with severe infection].
    Wang Y; Chen X; Guo X; Cao K; Zhu Z; Zhang B; Liang P; Yu W
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Jun; 32(6):716-720. PubMed ID: 32684219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study.
    Rigatto MH; Behle TF; Falci DR; Freitas T; Lopes NT; Nunes M; Costa LW; Zavascki AP
    J Antimicrob Chemother; 2015 May; 70(5):1552-7. PubMed ID: 25604744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rare occurrence of polymyxin B-induced hyperpigmentation in a child with ventriculitis.
    Fitzrol DN; Ang SY; Suhaimi A; Yeap TB
    BMJ Case Rep; 2023 Apr; 16(4):. PubMed ID: 37041040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nephrotoxicity and efficacy assessment of polymyxin use in 92 transplant patients.
    Mostardeiro MM; Pereira CA; Marra AR; Pestana JO; Camargo LF
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1442-6. PubMed ID: 23295926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurotoxicity in adult patients with cystic fibrosis using polymyxin B for acute pulmonary exacerbations.
    Rekis N; Ambrose M; Sakon C
    Pediatr Pulmonol; 2020 May; 55(5):1094-1096. PubMed ID: 32168426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium.
    Tuon FF; Rigatto MH; Lopes CK; Kamei LK; Rocha JL; Zavascki AP
    Int J Antimicrob Agents; 2014 Apr; 43(4):349-52. PubMed ID: 24439066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.